Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Axsome Therapeutics Inc

AXSM
Current price
93.35 USD +3.35 USD (+3.72%)
Last closed 86.43 USD
ISIN US05464T1043
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 202 897 408 USD
Yield for 12 month +43.50 %
1Y
3Y
5Y
10Y
15Y
AXSM
21.11.2021 - 28.11.2021

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. Address: One World Trade Center, New York, NY, United States, 10007

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

123.75 USD

P/E ratio

Dividend Yield

Current Year

+270 600 000 USD

Last Year

+50 037 106 USD

Current Quarter

+87 166 000 USD

Last Quarter

+74 999 000 USD

Current Year

+237 701 000 USD

Last Year

+44 839 511 USD

Current Quarter

+77 258 000 USD

Last Quarter

+66 871 000 USD

Key Figures AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -261 380 992 USD
Operating Margin TTM -87.06 %
PE Ratio
Return On Assets TTM -28.23 %
PEG Ratio
Return On Equity TTM -161.69 %
Wall Street Target Price 123.75 USD
Revenue TTM 291 488 992 USD
Book Value 2.15 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 86.7 %
Dividend Yield
Gross Profit TTM 45 939 511 USD
Earnings per share -6.58 USD
Diluted Eps TTM -6.58 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -105.85 %

Dividend Analytics AXSM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AXSM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 13.9938
Price Sales TTM 14.4187
Enterprise Value EBITDA -14.8071
Price Book MRQ 40.8636

Financials AXSM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AXSM

For 52 weeks

55.02 USD 98.4 USD
50 Day MA 88.87 USD
Shares Short Prior Month 7 671 607
200 Day MA 81.99 USD
Short Ratio 17.33
Shares Short 7 758 630
Short Percent 19.4 %